Corline Biomedical AB (“Corline” or the “company”) will hold bolagspresentation at 15.00 on 23 may 2017 at Erik Penser Bank, and will update investors on the status of the company’s key development projects. The following information will be discussed.
The company is engaged in two focused development projects – Renaparin® to improve kidney transplantation and Cytoparin(TM) to increase the efficacy of cell therapy for patients with type 1 diabetes.
Renaparinprojektet is in an intense phase of development where the preparations to submit an application for a clinical trial to the Fda is underway. The company has during april and may of 2017 held two meetings with the Fda regarding the quality and produktionsfrågeställningar (CMC) and has subsequently launched its production of prövningssubstans in accordance with GMP in conjunction with external suppliers. The company’s goal is to initiate phase 1 studies with Renaparin® in 2017 and carry out a study with a total of 18 patients reported in 2018. Corline has received the first of two payments from the EU’s Horizon 2020 programme is about a total of about MSEK 23.1, which fully funds the study.
Cytoparinprojektet is approved by the Fda for the start of the clinical study, but the project has been deferred as a result of the discussion the company has, with the Nordic network for öcellstransplantation (NPITG). Corline has received a proposal from NPITG on shorter valideringsprojekt deemed to include a few months of work, to ensure that the Cytoparin-processing and the shipment of cellmaterial between Oslo and Stockholm, not causes nettonyttan of the treatment is compromised. In parallel with this process has Corline initiated discussions with additional clinical centers both in and outside the Nordic countries, in order to accelerate the study start and patientrekrytering. Based on the discussions Corline have held, the company assesses that the interest of the Cytoparin(TM) is among the clinics that the company is discussing with. The goal is to add centers to study before the upcoming holiday season. In parallel, we will continue cooperation with NPITG.
For questions, please contact
Henrik Nittmar, CEO
Telephone: 018-71 30 90
E-mail: henrik.nittmar@corline.se
Certified Adviser
Subsequently, the Brokerage is Corlines Certified Adviser.
This information is such information that Corline Biomedical AB is obliged to publish under the EU marknadsmissbruksförordning. The information was submitted, by the above contact person in the government, for publication on 22 may 2017.
Corline Biomedical AB
working with the endogenous substance heparin and has developed a portfolio of candidate drugs for use in conjunction with organ – and cell transplantation. The company is planning clinical studies in type 1 diabetes and kidney transplant, for which the Corline also has received särläkemedelsstatus (“Orphan Drug”). Within the framework of a wholly owned subsidiary of Corline Pharma AB evaluated the in vivo administration of Corlines heparinsubstans.
170522_PM – Corline – update development projects
